Integration of clinical information and molecular biology profile -Endeavor of SCRUM-Japan-
Related Experiment Video
Updated: Feb 1, 2026

Extraction of Histones from Clinical Specimens for Epigenetic Profiling by Mass Spectrometry
Published on: November 21, 2025
Abstract:
In recent years, the cancer therapy based on the biomarker has been clinically introduced in colorectal cancer. Furthermore, the therapeutic development for the colorectal cancer patients corresponding to gene alteration, such as BRAF gene mutation and microsatellite instability(MSI), are underway. Although the development of the novel treatments according to biomarkers is urgent the fragmentation of the patient population by biomarker have caused various problems in the treatment development. To accelerate the development of therapeutic agents for small population, we conduct a nationwide genome screening project'SCRUM- Japan'.
Insights
Biomarker-driven therapies are advancing colorectal cancer treatment. To overcome challenges in developing drugs for small patient groups, the nationwide SCRUM-Japan genome screening project was initiated.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Biomarker-based therapies are increasingly used in colorectal cancer (CRC).
- Development of targeted therapies for genetic alterations like BRAF mutations and microsatellite instability (MSI) is ongoing for CRC patients.
- Fragmented patient populations based on biomarkers pose challenges for developing novel treatments.
Purpose of the Study:
- To accelerate the development of therapeutic agents for rare or small patient populations in CRC.
- To address the challenges posed by biomarker-driven patient stratification in drug development.
Main Methods:
- Implementation of a nationwide genome screening project named 'SCRUM-Japan'.
- Focus on identifying patients with specific gene alterations relevant to CRC treatment.
Main Results:
- The SCRUM-Japan project aims to facilitate the development of targeted therapies.
- Facilitates enrollment of patients into clinical trials based on identified genomic profiles.
Conclusions:
- Nationwide genome screening projects like SCRUM-Japan are crucial for advancing precision medicine in oncology.
- Accelerating the development of novel treatments for biomarker-defined patient subgroups in colorectal cancer is achievable through collaborative screening efforts.
Related Concept Videos
What is Conservation Biology?
Integration by Parts: Indefinite Integrals
Molecular Models
Biological Effects of Radiation
Integration by Parts: Definite Integrals
Molecular Orbital Theory II

